Drug Repurposing in the Chemotherapy of Infectious Diseases (2024)

Peer-Reviewed Study · Amal Hamid; Pascal Mäser; Abdelhalim Babiker Mahmoud · January 29, 2024

Amal Hamid et al., 2024-01-29: Review of drug repurposing for infectious disease whose section 4.3 ('Lack of Intellectual Property Protection') states that off-patent or generic status discourages companies from investing in repurposing.

Repurposing existing drugs often involves the use of off-patent or generic drugs. This limits the potential for exclusivity and intellectual property protection, which can discourage pharmaceutical companies from investing in repurposing efforts, as they may not see significant financial return

Amal Hamid et al., 2024-01-29: Review of drug repurposing for infectious disease whose section 4.3 ('Lack of Intellectual Property Protection') states that off-patent or generic status discourages companies from investing in repurposing. C1, general statement only. Review article, no data. Methylene blue appears in this review solely in the historical introduction (as Ehrlich-era antimalarial), not in the intellectual-property passage, so this documents the authors' general position on off-patent drugs and not a methylene-blue-specific funding statement. No methylene-blue-specific statement that research is hard to fund because it is off-patent was found in the peer-reviewed literature searched. text_file=A_06.txt Study type: review.